Education
About Us
Working with TipRanks
Follow Us
Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
2509 Stock Chart & Stats
HK$28.58
HK$0.02(0.29%)
At close: 4:00 PM EST
HK$28.58
HK$0.02(0.29%)
Day’s Range― - ―
52-Week RangeHK$6.30 - HK$36.50
Previous CloseN/A
Volume3.00K
Average Volume (3M)305.01K
Market Cap
HK$4.66B
Enterprise ValueHK$4.16B
Total Cash (Recent Filing)HK$558.90M
Total Debt (Recent Filing)HK$635.93M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding227,071,600
10 Day Avg. Volume194,489
30 Day Avg. Volume305,010
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)6.64
Price to Sales (P/S)9.58
P/FCF Ratio-8.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.00Price Target Upside15.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe substantial revenue growth indicates strong market demand and successful product adoption, which can support long-term business expansion and investment in R&D.
Gross Profit Margin ImprovementImproved gross profit margins suggest better cost management and operational efficiency, enhancing the company's ability to reinvest in growth initiatives.
Strategic PartnershipsStrategic partnerships provide access to additional resources, expertise, and markets, potentially accelerating product development and commercialization.
Bears Say
High LeverageHigh leverage can increase financial risk and limit flexibility, potentially impacting the company's ability to invest in growth or weather economic downturns.
Negative ProfitabilityOngoing profitability challenges can hinder the company's ability to generate sustainable cash flows and fund future growth without external financing.
Negative Cash FlowNegative cash flow indicates that the company is not generating enough cash from operations to cover its expenses, which may necessitate additional financing.
Qyuns Therapeutics Co., Ltd. Class H News
2509 FAQ
What was Qyuns Therapeutics Co., Ltd. Class H’s price range in the past 12 months?
Qyuns Therapeutics Co., Ltd. Class H lowest stock price was HK$6.30 and its highest was HK$36.50 in the past 12 months.
What is Qyuns Therapeutics Co., Ltd. Class H’s market cap?
Qyuns Therapeutics Co., Ltd. Class H’s market cap is HK$4.66B.
When is Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date?
Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date is Mar 27, 2026 which is in 31 days.
How were Qyuns Therapeutics Co., Ltd. Class H’s earnings last quarter?
Qyuns Therapeutics Co., Ltd. Class H released its earnings results on Aug 15, 2025. The company reported -HK$0.137 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.137.
Is Qyuns Therapeutics Co., Ltd. Class H overvalued?
According to Wall Street analysts Qyuns Therapeutics Co., Ltd. Class H’s price is currently Undervalued.
Does Qyuns Therapeutics Co., Ltd. Class H pay dividends?
Qyuns Therapeutics Co., Ltd. Class H does not currently pay dividends.
What is Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate?
Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qyuns Therapeutics Co., Ltd. Class H have?
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding.
What happened to Qyuns Therapeutics Co., Ltd. Class H’s price movement after its last earnings report?
Qyuns Therapeutics Co., Ltd. Class H reported an EPS of -HK$0.137 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.248%.
Which hedge fund is a major shareholder of Qyuns Therapeutics Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2509
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qyuns Therapeutics Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.56%
12-Months-Change
Fundamentals
Return on Equity
-64.62%
Trailing 12-Months
Asset Growth
7.41%
Trailing 12-Months
Company Description
Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializes in research, development, and commercialization of biopharmaceutical products, leveraging cutting-edge technology and scientific research to address unmet medical needs. Qyuns Therapeutics aims to provide novel treatment options through its pipeline of drug candidates, enhancing patient care and outcomes.
2509 Stock 12 Month Forecast
Average Price Target
HK$33.00
▲(15.47% Upside)
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―